Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis
Journal of Clinical Medicine · 01.06.2025 · 14 (11) · 3890
DOI: 10.3390/jcm14113890 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.06.2025. Verfasst von Cristina Martinez-Molina und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Division of Medicines, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review aimed to provide a comprehensive overview of the current landscape of etrasimod. Etrasimod is an oral, once-daily selective modulator of sphingosine 1-phosphate receptors (S1PR), developed for the treatment of moderately to severely active ulcerative colitis and currently being explored for its potential in other immune-mediated inflammatory diseases. It selectively targets the S1PR subtypes S1PR1, S1PR4, and S1PR5, with limited activity on S1PR3 and no activity on S1PR2. Clinical trials have demonstrated that etrasimod significantly reduces symptoms and induces endoscopic improvement in patients with moderate to severe ulcerative colitis who are refractory or intolerant to at least one conventional therapy, biologic agent, or Janus kinase inhibitor, while maintaining a favourable safety profile. At the end of 2023, etrasimod was approved in the United States and Europe, and it is currently under review for ulcerative colitis in several other regions. Etrasimod offers a novel therapeutic option with unique characteristics that may help address the persistent unmet needs of real-world patients with moderately to severely active ulcerative colitis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Division of Medicines, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
- Endoscopy Unit, Department of Gastroenterology, Clinical Institute of Digestive and Metabolic Diseases (ICMDM), Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
ORCID-Profile: Cristina Martinez-Molina, Begoña González-Suárez
Zitieren
APA
Martinez-Molina, C., & González-Suárez, B. (2025). Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis. Journal of Clinical Medicine, 14(11), 3890. https://doi.org/10.3390/jcm14113890
Vancouver
Martinez-Molina C, González-Suárez B. Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis. Journal of Clinical Medicine. 2025;14(11):3890. doi:10.3390/jcm14113890
BibTeX
@article{MartinezMolina2025,
author = {Martinez-Molina, Cristina and González-Suárez, Begoña},
title = {Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {11},
pages = {3890},
doi = {10.3390/jcm14113890}
}
EUVIMED